Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Summary

FDA approved drugs to treat patients with relapsed or refractory anaplastic large cell lymphoma (ALCL) has a median progression free survival of 20 months. Majority of patients relapse in 2 years. This study will evaluate overall response rate of next generation ALK inhibitor brigatinib in ALK positive ALCL patients by overcoming mechanisms of resistance to ALK inhibitors on cancer patients.

Timeline

Start

2018-12-06

Primary completion

2020-03-18

Completion

2020-06-16

Drugs

Indications